Lovenox HP

• Fibrinolytic Agents
• Anticoagulants
• Heparins
• ATC:B01AB05

• Clexane
• Enoxaparin sodium
• Lovenox
• Lovenox HP
• Low Molecular Weight Heparin
• LMWH

• No information avaliable

(C₂₆H₄₀N₂O₃₆S₅)n

http://www.rxlist.com/cgi/generic3/lovenox.htm

Lovenox_HP FDA

J. Mardiguian, Eur. pat. Appl. 40,144 (1981 to Pharmindustrie), C.A. 96, 218191s (1982)

4500 daltons (average)

No information avaliable

> 200 mg/mL

Solid

No information avaliable

Solution (for subcutaneous injection)

For the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism, and also for the prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction, when concurrently administered with aspirin.

Enoxaparin is a highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Enoxaparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Enoxaparin is a well known and commonly used anticoagulant which has antithrombotic properties. Enoxaparin inhibits reactions that lead to the clotting of blood and the formation of fibrin clots both in vitro and in vivo. Enoxaparin acts at multiple sites in the normal coagulation system. Small amounts of enoxaparin in combination with antithrombin III (enoxaparin cofactor) can inhibit thrombosis by inactivating activated Factor X and inhibiting the conversion of prothrombin to thrombin. Once active thrombosis has developed, larger amounts of enoxaparin can inhibit further coagulation by inactivating thrombin and preventing the conversion of fibrinogen to fibrin. Enoxaparin also prevents the formation of a stable fibrin clot by inhibiting the activation of the fibrin stabilizing factor.

Mean absolute bioavailability of enoxaparin, after 1.5 mg/kg given subcutaneously, based on anti-Factor Xa activity is approximately 100% in healthy volunteers.

Mouse, median lethal dose greater than 5000 mg/kg. Another side effect is heparin induced thrombocytopenia (HIT syndrome). HIT is caused by an immunological reaction that makes platelets form clots within the blood vessels, thereby using up coagulation factors.

No information avaliable

Humans and other mammals